Eckert+Ziegler wants to divest Pentixapharm AG and take advantage of the high growth opportunities in radioisotopes. A smart move!

Eckert+Ziegler wants to leverage the true value of Pentixapharm AG. The ideal scenario would be to sell it to a pharmaceutical company within the next few months. Focusing on radioisotopes is a good idea. Eckert+Ziegler sees tremendous growth opportunities, as evidenced by incoming orders, as targeted radiation therapies begin to establish themselves. Eckert+Ziegler came out with exciting news. They want to spin off Pentixapharma AG. It has a diagnostic in phase III, which is a radiopharmaceutical combination product. This pathes the...